ReviewJournal of perinatology : official journal of the California Perinatal Association2026
Reconsidering transcutaneous bilirubinometry for management of neonatal hyperbilirubinemia: is it time for change?
Review in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite growing concerns about the adverse effects of painful procedures in neonates, current guidelines continue to recommend using total serum bilirubin (TSB) levels to make decisions in the treatment of hyperbilirubinemia. Transcutaneous bilirubin assessment (TcB) has been studied extensively, but its presumed reliability is only based on how well it correlates with TSB. This assumes that TSB is the "gold standard" for determining the risk of bilirubin-induced neurotoxicity, although there is no direct evidence linking specific TSB levels to that risk. Furthermore, TSB levels are subject to variability due to the margin of error of the laboratory analysis. TcBs avoid skin-breaking procedures and have the additional advantages of decreased turn-around time, nursing and laboratory staff time, and costs. TcB procedures could be standardized, and new guidelines with increased reliance on them could significantly reduce painful procedures in these patients without increasing the risk of bilirubin neurotoxicity.
Indexed as
Identifiers
41490925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.